EvolutionaryScale vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 55)
EvolutionaryScale logo

EvolutionaryScale

ChallengerHealthcare & Life Sciences

AI Protein Design & Biology

AI biology lab building protein design models (ESM3, 98B params). Founded 2023 by ex-Meta scientists. $142M seed. Acquired by Chan Zuckerberg Biohub Nov 2025.

AI VisibilityBeta
Overall Score
C55
Category Rank
#170 of 596
AI Consensus
72%
Trend
stable
Per Platform
ChatGPT
53
Perplexity
61
Gemini
57

About

EvolutionaryScale was an AI research lab founded in 2023 by former Meta AI protein team scientists, including CEO Alexander Rives. Based in New York City, the company developed frontier AI models for protein design and biological discovery. Its flagship model ESM3 is a 98-billion-parameter generative AI system trained on 2.78 billion protein sequences capable of reasoning over protein sequence, structure, and function simultaneously.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
up
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

55
Overall Score
90
#170
Category Rank
#2
72
AI Consensus
83
stable
Trend
up
53
ChatGPT
92
61
Perplexity
93
57
Gemini
89
49
Claude
96
57
Grok
95

Key Details

Category
AI Protein Design & Biology
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only EvolutionaryScale
AI Protein Design & Biology

Integrations

Only Moderna
Moderna is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.